Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 1993;7:2135–48.

Article  CAS  PubMed  Google Scholar 

Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature. 1994;369:156–60.

Article  CAS  PubMed  Google Scholar 

Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996;15:2760–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239–52.

Article  CAS  PubMed  Google Scholar 

Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol. 2014;171:24–37.

Article  CAS  Google Scholar 

de Los Reyes Corrales T, Losada-Perez M, Casas-Tinto S. JNK pathway in CNS pathologies. Int J Mol Sci. 2021;22:3883.

Article  Google Scholar 

Feng GT, Yang X, Shuai W, Wang G, Ouyang L. Update on JNK inhibitor patents: 2015 to present. Expert Opin Ther Pat. 2024;34:907–27.

Article  CAS  PubMed  Google Scholar 

Yan HY, He LF, Lv D, Yang J, Yuan Z. The role of the dysregulated JNK signaling pathway in the pathogenesis of human diseases and its potential therapeutic strategies: a comprehensive review. Biomolecules. 2024;14:243.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu QH, Wu WD, Jacevic V, Franca TCC, Wang X, Kuca K. Selective inhibitors for JNK signalling: a potential targeted therapy in cancer. J Enzym Inhib Med Chem. 2020;35:574–83.

Article  CAS  Google Scholar 

Bennett BL, Sasaki DT, Murray BW, O’Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA. 2001;98:13681–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scapin G, Patel SB, Lisnock J, Becker JW, LoGrasso PV. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem Biol. 2003;10:705–12.

Article  CAS  PubMed  Google Scholar 

Heo YS, Kim SK, Seo CI, Kim YK, Sung BJ, Lee HS, et al. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J. 2004;23:2185–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang HY, Hsu HC, Fang YH, Liu PY, Liu YW. Empagliflozin attenuates doxorubicin-induced cardiotoxicity by inhibiting the JNK signaling pathway. Biomed Pharmacother. 2024;176:116759.

Article  CAS  PubMed  Google Scholar 

Al-Tamimi M, Khan AQ, Anver R, Ahmad F, Mateo JM, Raza SS, et al. Pristimerin mediated anticancer effects and sensitization of human skin cancer cells through modulation of MAPK signaling pathways. Biomed Pharmacother. 2022;156:113950.

Article  CAS  PubMed  Google Scholar 

Gu L, He X, Zhang YQ, Li SL, Tang J, Ma R, et al. Fluorofenidone protects against acute liver failure in mice by regulating MKK4/JNK pathway. Biomed Pharmacother. 2023;164:114844.

Article  CAS  PubMed  Google Scholar 

Zhang P, Wang Q, Chen J, Ci Z, Zhang W, Liu Y, et al. Chondrogenic medium in combination with a c-Jun N-terminal kinase inhibitor mediates engineered cartilage regeneration by regulating matrix metabolism and cell proliferation. Regen Biomater. 2023;10:rbad079.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidt M, Budirahardja Y, Klompmaker R, Medema RH. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep. 2005;6:866–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joiakim A, Mathieu PA, Palermo C, Gasiewicz TA, Reiners JJ. The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor. Drug Metab Dispos. 2003;31:1279–82.

Article  CAS  PubMed  Google Scholar 

Dvorak Z, Vrzal R, Henklova P, Jancova P, Anzenbacherova E, Maurel P, et al. JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes. Biochem Pharmacol. 2008;75:580–8.

Article  CAS  PubMed  Google Scholar 

Ross D, Siegel D. The diverse functionality of NQO1 and its roles in redox control. Redox Biol. 2021;41:101950.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bianchet MA, Faig M, Amzel LM. Structure and mechanism of NAD[P]H:quinone acceptor oxidoreductases (NQO). Methods Enzymol. 2004;382:144–74.

Article  CAS  PubMed  Google Scholar 

Faig M, Bianchet MA, Talalay P, Chen S, Winski S, Ross D, et al. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc Natl Acad Sci USA. 2000;97:3177–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oh ET, Park HJ. Implications of NQO1 in cancer therapy. BMB Rep. 2015;48:609–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen LP, Jiang S, Yang Y, Yang HL, Fang YC, Tang M, et al. Pan-cancer and single-cell analysis reveal the prognostic value and immune response of NQO1. Front Cell Dev Biol. 2023;11:1174535.

Article  PubMed  PubMed Central  Google Scholar 

Oh ET, Kim HG, Kim CH, Lee JH, Kim C, Lee JS, et al. NQO1 regulates cell cycle progression at the G2/M phase. Theranostics. 2023;13:873–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asher G, Dym O, Tsvetkov P, Adler J, Shaul Y. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol. Biochemistry. 2006;45:6372–8.

Article  CAS  PubMed  Google Scholar 

Zhou YJ, Chen YX, Xuan CY, Li XY, Tan YY, Yang MD, et al. DPP9 regulates NQO1 and ROS to promote resistance to chemotherapy in liver cancer cells. Redox Biol. 2024;75:103292.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Mu XW, Yang Q, Luo JJ, Zhao YJ. Hypoxia-responsive nanocarriers for chemotherapy sensitization via dual-mode inhibition of hypoxia-inducible factor-1 alpha. J Colloid Interface Sci. 2022;628:106–15.

Article  CAS  PubMed  Google Scholar 

Ma N, Zhang MW, Hu JQ, Wei ZT, Zhang SL. Daphnetin induces ferroptosis in ovarian cancer by inhibiting NAD(P)H:Quinone oxidoreductase 1 (NQO1). Phytomedicine. 2024;132:155876.

Article  CAS  PubMed  Google Scholar 

Luo ZY, Li Q, He S, Liu SQ, Lei R, Kong Q, et al. Berberine sensitizes immune checkpoint blockade therapy in melanoma by NQO1 inhibition and ROS activation. Int Immunopharmacol. 2024;142:113031.

Article  CAS  PubMed